StemSynergy Therapeutics Inc. (SSTI) is a biopharmaceutical company that focuses on the discovery and development of small-molecule drugs targeting developmental pathways fundamental to cancer. The goal of the company's cancer program is to develop novel therapeutics to treat cancer by targeting cellular processes that are deregulated in cancer stem cells. Its drugs act in combination with standard-of-care agents that target the bulk of the cancer cells, with the overall aim of eliminating the cancer. SSTI is focused on breakthrough technologies in WNT and Sonic Hedgehog (SHH) signaling. In January 2018 StemSynergy Inc. and Exelixis Inc. joined forces to develop new cancer compounds that target casein kinase 1 alpha (CK1a), a component of the Wnt signaling pathway.
